ResMed Q2 2025 Earnings Report
Key Takeaways
ResMed Inc. reported a 10% increase in revenue to $1.3 billion, a 52% increase in operating profit, and a 19% increase in non-GAAP operating profit for the second quarter of fiscal year 2025. The company's diluted earnings per share was $2.34, with a non-GAAP diluted earnings per share of $2.43. Operating cash flow was $309 million.
Revenue increased by 10% to $1.3 billion; up 10% on a constant currency basis.
Gross margin improved 300 bps to 58.6%; non-GAAP gross margin improved 230 bps to 59.2%.
Income from operations increased 52%; non-GAAP income from operations up 19%.
Diluted earnings per share of $2.34; non-GAAP diluted earnings per share of $2.43.
ResMed
ResMed
ResMed Revenue by Geographic Location
Forward Guidance
ResMed provided forward guidance, but the details were not specified in the provided text.
Revenue & Expenses
Visualization of income flow from segment revenue to net income